Zogenix (ZGNX) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ZGNX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHwasung Industrial Co Ltd 002460morningstar.com - March 23 at 1:30 AMAlcon (NYSE: ALC)fool.com - July 6 at 8:34 PMLongeveron Inc Ordinary Shares - Class Amorningstar.com - May 21 at 12:24 AMHow Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business Wirebusinesswire.com - October 11 at 6:56 PMBiocryst Pharmaceuticalsforbes.com - September 30 at 6:22 PMNippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.commarketscreener.com - September 26 at 12:15 PMPROMIS NEUROSCIENCES INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.commarketscreener.com - September 13 at 9:39 AMHow Women Lead appoints three new executive board members - Bizwomen - The Business Journalsbizjournals.com - September 10 at 4:49 PMEast Bay Biotech Companies - San Francisco Business Times - The Business Journalsbizjournals.com - September 9 at 12:53 PMOncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - PR Newswireprnewswire.com - September 9 at 7:53 AMOncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - StreetInsider.comstreetinsider.com - September 8 at 6:49 AMOncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - Yahoo Financefinance.yahoo.com - September 7 at 3:45 PMWith early-cancer detection technology, Delfi Diagnostics looks to beat out Guardant Health, Illumina's Grail and others - San Francisco Business Times - The Business Journalsbizjournals.com - August 30 at 6:56 PMDepomed Reports Dip in Earnings, Reduces Revenue Guidancethestreet.com - August 29 at 7:05 PMDelfi Diagnostics Adds Finance and Market Access Leadership as It Prepares for Commercial Launch - PR Newswireprnewswire.com - August 23 at 9:25 AMNuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - Business Wirebusinesswire.com - August 16 at 8:44 AMNuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - StreetInsider.comstreetinsider.com - August 15 at 6:52 PMDravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% - ResearchAndMarkets.com - Business Wirebusinesswire.com - August 9 at 5:29 PMTevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board - StreetInsider.comstreetinsider.com - August 3 at 7:58 AMGeno Hires First Chief Legal Officer on Path to Accelerate the Transition to More Sustainable Materials - PR Newswireprnewswire.com - August 2 at 10:47 AMUCB : Strong first six months – UCB with continued delivery and strong resilience - Marketscreener.commarketscreener.com - July 28 at 3:32 AMAdamis Appoints Vickie Reed to Board of Directors - GuruFocus.comgurufocus.com - June 25 at 10:51 PMUCB : updates financial guidance for 2022 while maintaining 2025 financial guidance - Marketscreener.commarketscreener.com - June 24 at 1:57 AMADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology - Business Wirebusinesswire.com - June 8 at 8:21 PMUCB's therapy gets FDA orphan drug status to treat seizures linked with rare epilepsy - Seeking Alphaseekingalpha.com - June 8 at 10:20 AMADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology - StreetInsider.comstreetinsider.com - June 7 at 7:19 PMAdamis Appoints Vickie Reed to Board of Directors - StreetInsider.comstreetinsider.com - May 27 at 7:42 AMSuneva Medical Inc. Announces Multiple Regulatory Approvals in the U.S. and Canadamarkets.businessinsider.com - May 6 at 12:09 AMNorton Rose Adds Brussels Antitrust Pro From Covington - Law360law360.com - April 19 at 3:59 PMU.S. FDA approves UCB's drug for rare childhood epilepsy - Marketscreener.commarketscreener.com - March 28 at 7:35 AMU.S. FDA approves UCB's drug for rare childhood epilepsy - Reuters.comreuters.com - March 28 at 2:34 AMForm POS AM ZOGENIX, INC. - StreetInsider.comstreetinsider.com - March 7 at 9:19 PMUCB completes $1.9B acquisition of Zogenix - Seeking Alphaseekingalpha.com - March 7 at 9:19 PMUCB Completes Acquisition of Zogenix, Inc. - Benzinga - Benzingabenzinga.com - March 7 at 9:19 PMUCB Completes Acquisition of Zogenix, Inc. - PR Newswireprnewswire.com - March 7 at 9:19 PMUCB Completes Acquisition of Zogenix, Inc.finance.yahoo.com - March 7 at 9:19 PMZogenix : Amendment to Annual Report (Form 10-K/A) - Marketscreener.commarketscreener.com - March 7 at 10:56 AMmarketbeat.com - March 7 at 6:01 AMZogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 - Yahoo Financefinance.yahoo.com - March 6 at 6:23 PMZogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN - Benzingabenzinga.com - March 4 at 10:15 PMZogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 - StreetInsider.comstreetinsider.com - March 4 at 4:11 PMZogenix To Present New Long-term Data On FINTEPLA (fenfluramine) In Lennox-Gastaut Syndrome (LGS) At AAN 2022 From April 2-7 - Benzingabenzinga.com - March 4 at 4:11 PMZogenix To Present New Long-term Data on FINTEPLA® - GlobeNewswireglobenewswire.com - March 4 at 4:11 PMZogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022finance.yahoo.com - March 4 at 4:11 PMZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results - Yahoo Financefinance.yahoo.com - March 2 at 3:09 AMZOGENIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-K) - Marketscreener.commarketscreener.com - March 1 at 10:08 PMUCB Announces Extension of Tender Offer to Acquire Zogenix, Inc. - marketscreener.commarketscreener.com - March 1 at 12:06 PMZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results - GlobeNewswireglobenewswire.com - March 1 at 12:06 PMRecap: Zogenix Q4 Earnings - Benzingabenzinga.com - February 28 at 4:27 PMZogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimatesfinance.yahoo.com - February 28 at 4:27 PM Get Zogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better. Click here to find out that this 8,788% cryptocurrency is. ZGNX Media Mentions By Week ZGNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZGNX News Sentiment▼0.200.44▲Average Medical News Sentiment ZGNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZGNX Articles This Week▼00▲ZGNX Articles Average Week Get Zogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SUPN News PCRX News PTCT News CORT News ORIC News STOK News NKTX News BTAI News XENE News PRGO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZGNX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
